• Ian D Pavord, MA DM FRCP FERS FMedSci is Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals. He is a member of congregation at the University of Oxford and a Professorial Fellow of St Edmund Hall. He was a Consultant Physician from 1995 and Honorary Professor of Medicine from 2005 to 2013 at the Institute for Lung Health, Glenfield Hospital, University Hospitals of Leicester NHS Trust. He was elected an NIHR Senior Investigator in 2011, a Fellow of the European Respiratory Society in 2014 and a Fellow of the Academy of Medical Science in 2015. He has a research interest in the clinical aspects of inflammatory airway diseases and he has pioneered the use of non-invasive measures of airway inflammation in the assessment of these conditions. He has identified a number of clinically important phenotypes of inflammatory airway disease and has played a lead role in the clinical development of three of the most promising new treatments for severe airway disease. Professor Pavord was co-editor of Thorax from 2010-2015, Chief Medical Officer of Asthma UK from 2008-14 and Associate Editor of the American Journal of Respiratory and Critical Care Medicine from 2005-10. He is the author of more than 355 publications including 6 in the New England Journal of Medicine and 11 in the Lancet. He received the 2016 European Respiratory Society (ERS) Gold Medal for his research and gave the Cournand Lecture at the 2004 ERS meeting, the second UK based researcher to have been given this honour.

    • Thoracic and Cardiac Surgery
    • Chair and Professor of Thoracic Medicine and Surgery at Lewis Katz School of Medicine at Temple University

    Gerard Criner, MD, is Chair and Professor of Thoracic Medicine and Surgery at Lewis Katz School of Medicine at Temple University in Philadelphia, PA, where he also obtained his medical degree in 1989. Dr Criner completed his internship and residency in internal medicine at Temple University Hospital, and his fellowship in pulmonary and critical care medicine at Boston University School of Medicine in Boston, MA. Dr Criner is committee member of the Intensive Care Unit Committee at Temple University Hospital and executive director of Philadelphia Critical Care Society. He also serves on the board of directors for the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and acts as Chairman for the ACCP guidelines on the prevention of acute exacerbations in chronic obstructive pulmonary disease (COPD). He is a member of the board of directors for the Global Initiative for Chronic Obstructive Lung Disease. In 2013, Dr Crimer was the recipient of the Paul W. Eberman Faculty Research Award from Temple University. As a principal investigator, Dr Criner has received extensive research funding and has conducted several clinical trials in pulmonary disease. His primary research focuses on advanced lung conditions, including COPD, emphysema, pulmonary fibrosis, pulmonary hypertension, and respiratory failure. Dr Criner has published over 300 scientific papers, reviews, and book chapters, with numerous research articles in peer- reviewed journals including New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine (AJRCCM), Chest and Lancet Respiratory Medicine. He serves on the editorial review board of Advances for Respiratory Care Managers and AJRCCM. Dr Criner has lectured nationally and internationally at numerous scientific meetings and congresses.

    • Pulmonary Disease

    Dr. Frank Sciurba, M.D. is a Professor at the University of Pittsburgh School of Medicine, Director of the Emphysema/COPD research center, and director of the clinical pulmonary physiology laboratories and pulmonary rehabilitation program. He received his undergraduate degree in Biochemistry from the University of Illinois and attended Medical school at the University of Chicago Pritzker School of Medicine. Dr. Sciurba’s research has been inspired by real clinical problems facing his patients. He has co-authored over 200 manuscripts and has had continuous NIH funding for 20 years. Dr. Sciurba's current leadership positions include: His role as a Principle Investigator of the Network Management Core of the new NHLBI sponsored Pulmonary Trials Consortium (PTC) which manages the execution of pragmatic, “real world” studies in a variety of chronic pulmonary conditions; and his role as academic chair of the COPD Biomarker Qualification Committee (CBQC), a group that works with the FDA to address the need for new biomarkers to facilitate development of drugs and devices for chronic pulmonary conditions. He is also currently the chair of the American Thoracic Society Clinical Problems Program Committee.

    • Medical Development leader for Mepolizumab at GlaxoSmithKline Pharmeceuticals

    Steve Yancey received his Masters Degree in physiology from North Carolina State University. This was followed by a period of academic research in reproductive physiology and chronobiology Mr. Yancey began a career in the Pharmaceutical Industry (GSK) in 1987. He has over 50 publications in peer-reviewed journals. He has contributed to the development of inhaled bronchodilators, inhaled corticosteroids, and biologic medicines for patients with respiratory diseases. Mr. Yancey has also led teams focused on establishing drug safety profiles and currently leads a global team developing a biological therapy for respiratory and other associated diseases.

Powered by Medstro